reactive arthritis: Reactive arthritis (ReA) is an autoimmune disorder belonging to the group of seronegative spondyloarthropathies and is characterized by the classic triad of arthritis, urethritis and conjunctivitis.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
220 |
4. Check minimum number of eventsNone |
220 |
5. Include endpointsNone |
220 |
6. Filter based on genotype QC (FinnGen only) |
214 |
Control definitions (FinnGen only)
- Control exclude
- RHEUMA_ARHTROPAT_REACTIVE
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M02
- Name in latin
- Morbus Reiter
Similar endpoints
↥List of similar endpoints to
Reiter disease
based on the number of shared cases.
Similar with more cases:
- Reactive arthropathies, FINNGEN
- Finngen Rheumatological endpoints
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: unknown.
No upset table: unknown.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1810 | 445 | 1350 |
| Only index persons | 1625 | 422 | 1203 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.01 | 0.04 |
| Only index persons | 0.04 | 0.02 | 0.05 |
| Median age at first event (years) | |||
| Whole population | 43.46 | 44.10 | 43.14 |
| Only index persons | 42.52 | 43.47 | 42.19 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 214 | 68 | 146 |
| Unadjusted period prevalence (%) | 0.05 | 0.02 | 0.07 |
| Median age at first event (years) | 42.47 | 38.66 | 44.24 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 220
- Matched controls
- 2200
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M02.3
ICD-10 Finland
Reiter disease
+∞
296.5
212
*
A07EC01
ATC
sulfasalazine; oral, rectal
35.0
157.4
123
77
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
23.7
129.3
126
118
L04AX03
ATC
methotrexate; systemic
14.1
78.4
91
105
L01BA01
ATC
methotrexate; systemic
27.5
76.8
56
27
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
17.5
73.7
69
56
M02.9
ICD-10 Finland
Reactive arthropathy, unspecified
391.2
60.5
58
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
12.9
53.5
59
61
H20.0
ICD-10 Finland
Acute and subacute iridocyclitis
11.5
33.0
37
38
M45
ICD-10 Finland
Ankylosing spondylitis
13.2
30.7
31
27
M13.9
ICD-10 Finland
Arthritis, unspecified
7.4
29.0
48
80
P01BA02
ATC
hydroxychloroquine; oral
7.2
27.8
47
80
H02AB06
ATC
prednisolone; systemic
4.4
24.4
148
705
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
21.3
22.5
33
18
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
8.3
20.0
28
38
L04AA13
ATC
[U] leflunomide
22.7
19.6
28
14
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
19.4
19.3
29
17
S01BA01
ATC
dexamethasone; ophthalmic
9.0
19.2
25
31
13603
ICD-8 Finland
Other and unspecified infective and parasitic diseases, Morbus Reiter, syndroma urethro-oculo-articularis
+∞
19.0
18
*
M02.8
ICD-10 Finland
Other reactive arthropathies
206.9
18.8
19
*
H02AB07
ATC
prednisone; oral
4.6
18.1
51
136
L88
ICPC
Rheumatoid/seropositive arthritis
13.2
16.6
29
25
0993A
ICD-9 Finland
Other venereal diseases, Reiter's disease
+∞
13.7
13
*
S01BA04
ATC
prednisolone; ophthalmic
20.6
13.2
19
10
L04AB01
ATC
etanercept; parenteral
24.3
13.1
18
8
ZX120
NOMESCO Finland
Intravenous
4.2
12.7
38
105
L04AB04
ATC
adalimumab; parenteral
14.5
12.2
20
15
M46.9
ICD-10 Finland
Inflammatory spondylopathy, unspecified
21.4
11.3
16
8
S01FA02
ATC
scopolamine; ophthalmic
17.1
10.5
16
10
7111L
ICD-9 Finland
Arthropathy associated with infections, Arthropathy associated with Reiter's disease and nonspecific urethritis[UROARTHRITIS, USEAT NIVELET]
115.3
10.5
11
*
M07.3*L40.5
ICD-10 Finland
Other psoriatic arthropathies
13.0
10.0
17
14
S01CA02
ATC
prednisolone and antiinfectives; ophthalmic
21.2
9.9
14
7
N48.1
ICD-10 Finland
Balanoposthitis
7.8
9.8
22
31
H20.1
ICD-10 Finland
Chronic iridocyclitis
22.9
9.5
13
6
M02.1
ICD-10 Finland
Postdysenteric arthropathy
+∞
9.4
9
*
Z3231
NOMESCO Finland
Registered nurse
2.5
9.0
76
382
J01MA02
ATC
ciprofloxacin; systemic
2.4
9.0
99
562
M01AE03
ATC
ketoprofen; systemic, rectal
2.4
8.7
96
544
M13.0
ICD-10 Finland
Polyarthritis, unspecified
21.0
8.6
12
6
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
8.5
72
361
3640A
ICD-9 Finland
Disorders of iris and ciliary body, Acute and subacute iridocyclitis
93.5
8.5
9
*
M02.0
ICD-10 Finland
Arthropathy following intestinal bypass
+∞
8.4
8
*
L40.0
ICD-10 Finland
Psoriasis vulgaris
4.9
8.3
19
42
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
8.7
8.3
17
21
L40.5
ICD-10 Finland
Arthropathic psoriasis
12.4
8.2
14
12
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.5
8.2
64
309
M01AB55
ATC
diclofenac, combinations; oral
4.3
7.8
21
53
R5110, ,
SPAT
4.8
7.8
18
40
M01CB01
ATC
sodium aurothiomalate; parenteral
26.0
7.6
10
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
3.2
7.5
31
106
R4110
NOMESCO Finland
Physiotherapy
2.3
7.4
72
382
71490
ICD-8 Finland
Other specified forms of arthritis, Arthritis postinfectiosa NUD
31.1
7.2
9
*
M01AH01
ATC
celecoxib; oral
2.6
7.0
47
210
L04AA01
ATC
[U] ciclosporin
17.4
6.8
10
6
M01CB03
ATC
auranofin; oral
17.4
6.8
10
6
M01AC06
ATC
meloxicam; systemic, rectal
2.1
6.6
93
568
D07XC01
ATC
betamethasone; topical
2.7
6.5
37
151
N02AX02
ATC
tramadol; systemic, rectal
2.1
6.4
109
711
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.2
6.4
69
379
M13.1
ICD-10 Finland
Monoarthritis, not elsewhere classified
11.5
6.4
11
10
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
2.8
6.2
33
130
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
142
842
2.94
13.17
12.9
6.1
55.86
57.72
%
1.03
134
804
143
852
2.94
13.13
13.4
6.3
29.41
27.17
%
1.59
135
810
160
1021
3.08
12.79
15.7
10.3
4.32
4.11
e9/l
0.46
143
898
22
40
6.00
11.90
2.0
1.3
—
—
—
0
0
182
1279
3.45
11.71
8.7
3.9
10.51
10.83
mm/h
0.12
175
1190
180
1364
2.76
8.07
11.2
7.9
74.92
77.71
u/l
0.51
174
1287
57
264
2.56
7.91
1.3
1.3
9.95
5.58
u/ml
0.19
21
109
22
58
4.10
7.74
1.4
1.4
2.00
0.02
iu/ml
—
5
12
56
281
2.33
6.42
1.3
1.3
17.68
30.92
iu/ml
1.07
18
96
81
474
2.12
6.36
2.9
2.6
353.47
5422.92
umol/l
1.55
75
423
106
712
1.94
5.49
5.0
6.2
1.21
1.21
mmol/l
0.51
98
658
91
609
1.84
4.55
4.2
2.9
—
—
—
0
0
119
866
1.81
4.51
6.5
4.2
0.00
0.00
estimate
-0.00
33
174
118
860
1.80
4.42
5.1
3.1
0.00
0.01
estimate
0.50
34
181
49
270
2.05
4.34
3.6
2.7
4.24
1.57
e6/l
0.57
30
150
185
1561
2.16
4.32
25.7
16.2
14.04
14.65
%
1.57
185
1542
36
176
2.25
4.31
1.7
1.9
—
—
—
0
0
74
471
1.86
4.30
3.9
2.8
0.21
0.36
e6/l
0.86
59
353
118
875
1.75
4.04
5.2
3.1
0.00
0.00
estimate
-0.00
32
167
18
65
2.93
3.96
1.3
1.3
—
—
—
0
0
108
785
1.74
3.94
5.6
7.7
1.21
1.21
mmol/l
0.72
96
668
15
50
3.15
3.77
2.8
1.4
—
—
—
0
0
38
203
2.05
3.63
1.8
2.0
—
—
—
0
0
13
37
3.67
3.47
2.0
1.3
—
—
—
0
0
201
1793
2.40
3.45
21.6
13.4
21.20
23.17
mg/l
0.42
177
1413
17
67
2.67
3.21
1.6
2.5
—
—
—
0
0
11
30
3.80
3.13
1.9
2.8
4.54
3.98
e9/l
0.48
11
30
11
31
3.68
3.03
2.0
2.9
57.00
57.03
%
0.00
11
31
194
1735
2.00
2.85
18.1
12.2
87.31
84.70
ml/min/173m2
1.14
183
1441
68
470
1.65
2.80
5.9
3.1
0.00
0.00
estimate
-0.00
32
162
25
126
2.11
2.79
2.3
2.7
71.62
63.60
ml/min/173m2
0.53
13
60
10
29
3.56
2.73
1.1
1.5
—
—
—
0
0
10
29
3.56
2.73
1.1
1.5
—
—
—
0
0
46
291
1.73
2.62
3.6
2.6
0.63
0.89
e6/l
0.55
27
167
101
784
1.53
2.49
12.9
11.9
1.17
1.19
inr
0.08
31
241
6
13
4.71
2.28
4.3
4.1
—
—
—
0
0
5
9
5.65
2.22
1.4
1.1
104.72
222.71
iu/ml
—
5
9
143
1213
1.51
2.21
3.1
3.0
—
—
—
0
0
91
709
1.48
2.12
4.6
5.1
35.80
36.01
g/l
0.12
85
678
29
171
1.80
2.09
4.1
3.1
—
—
—
0
0
34
211
1.72
2.07
3.2
2.7
4.76
8.19
umol/l
2.28
27
184
89
697
1.47
2.00
5.3
3.1
—
—
—
0
0
19
99
2.01
1.97
5.3
10.1
93.37
94.06
%
0.18
19
99
51
357
1.56
1.95
1.2
1.2
0.68
0.92
u/ml
0.64
12
102
95
758
1.45
1.92
2.4
2.6
—
—
—
0
0
5
13
3.91
1.72
1.0
1.0
—
—
—
0
0
6
19
3.22
1.67
1.0
1.1
—
—
—
0
0
20
114
1.83
1.63
1.3
1.3
—
42.54
—
0
7
8
33
2.48
1.55
2.3
1.5
—
—
—
0
0
52
384
1.46
1.54
2.2
2.3
—
—
—
0
0
66
511
1.42
1.52
2.4
2.1
1197.89
171.43
u/l
0.48
56
482
9
39
2.36
1.45
1.6
1.5
—
—
—
0
0
16
89
1.86
1.41
3.6
7.4
23.29
24.74
mmol/l
1.08
16
89
41
294
1.48
1.40
3.1
3.7
0.81
0.82
mmol/l
0.28
36
282
189
1758
1.53
1.39
4.2
4.3
5.80
5.96
mmol/l
1.50
178
1623
51
383
1.43
1.38
1.8
1.8
0.76
1.33
mg/l
1.57
40
302
196
1839
1.60
1.37
17.9
14.9
139.76
139.71
mmol/l
0.10
196
1791
5
17
2.98
1.36
1.0
1.1
—
—
—
0
0
196
1847
1.56
1.25
18.0
15.0
3.95
3.99
mmol/l
1.29
196
1797
27
182
1.55
1.23
4.6
8.0
0.85
0.99
mmol/l
0.06
19
149
6
26
2.34
1.19
2.0
3.7
2.58
3.85
nmol/l
—
6
26
204
1945
1.67
1.17
22.4
15.4
79.59
80.37
umol/l
0.14
204
1945
8
39
2.09
1.16
2.1
1.6
—
—
—
0
0
8
39
2.09
1.16
1.3
1.2
—
—
—
0
0
121
1063
1.31
1.16
6.4
3.7
—
220.71
—
0
17
76
627
1.32
1.15
2.2
1.9
94.12
93.38
pmol/l
0.06
43
341
197
1865
1.54
1.14
5.0
4.7
2.81
2.81
mmol/l
0.01
191
1742
30
217
1.44
1.00
6.1
7.0
104.10
103.85
mmol/l
0.10
30
217
170
1580
1.33
1.00
4.0
4.2
1.73
1.88
mu/l
1.22
159
1433
12
69
1.78
0.98
5.1
1.9
—
—
—
0
0
5
23
2.20
0.98
1.0
1.1
—
—
—
0
0
25
175
1.48
0.98
1.4
1.3
—
—
—
0
0
0
32
0.00
0.96
0.0
1.4
—
—
—
0
0
38
292
1.36
0.91
3.6
3.5
318.45
277.13
ng/l
0.07
31
217
6
29
2.10
0.90
1.3
1.2
—
—
—
0
0
8
42
1.94
0.89
1.0
1.3
—
40.75
—
0
6
8
43
1.89
0.88
1.1
1.4
633.50
208.94
e6/l
—
8
35
17
112
1.56
0.88
1.4
1.6
—
—
—
0
0
46
367
1.32
0.87
2.2
1.9
2.91
3.30
mg/l
0.62
39
322
79
679
1.26
0.84
3.2
3.5
31.65
35.30
ng/l
0.13
49
453
8
46
1.77
0.83
1.5
1.3
—
—
—
0
0
6
32
1.90
0.82
1.2
3.0
—
945.40
—
0
5
11
66
1.70
0.80
2.4
3.4
—
—
—
0
0
0
24
0.00
0.79
0.0
1.4
—
—
—
0
0
0
24
0.00
0.79
0.0
1.4
—
—
—
0
0
0
24
0.00
0.79
0.0
1.4
—
—
—
0
0
39
309
1.32
0.78
1.4
1.4
—
—
—
0
0
0
27
0.00
0.78
0.0
1.3
—
161.41
—
0
27
15
99
1.55
0.78
2.4
1.6
—
—
—
0
0
7
38
1.87
0.74
1.9
1.3
—
—
—
0
0
26
195
1.38
0.73
1.9
1.8
—
—
—
0
0
7
39
1.82
0.73
1.9
7.8
—
161.50
—
0
8
5
25
2.02
0.73
1.0
1.0
—
—
—
0
0
5
26
1.94
0.71
2.2
2.1
—
—
—
0
0
5
26
1.94
0.71
3.2
3.5
—
—
—
0
0
179
1701
1.28
0.70
5.4
5.4
37.93
39.83
mmol/mol
2.91
174
1601
20
146
1.41
0.66
3.3
4.2
1.01
1.85
mmol/l
0.56
12
121
54
457
1.24
0.65
1.7
1.7
1.37
1.51
mmol/l
0.74
47
382
22
164
1.38
0.65
3.0
5.0
7.15
32.60
ug/l
0.49
17
136
15
210
0.69
0.64
6.4
7.6
—
—
—
0
0
0
22
0.00
0.59
0.0
2.2
—
22.04
—
0
7
36
294
1.27
0.59
2.1
2.1
1.60
1.47
%
0.34
29
263
44
371
1.23
0.55
2.1
1.6
28.05
20.28
nmol/l
0.37
38
323
15
108
1.42
0.54
1.6
1.4
—
—
—
0
0
33
270
1.26
0.54
1.8
1.9
—
—
—
0
0
6
39
1.55
0.53
1.8
1.6
—
—
—
0
0
190
1835
1.26
0.52
4.3
4.3
1.39
1.38
mmol/l
0.12
184
1713
78
700
1.18
0.52
3.7
2.6
251.53
162.45
ug/l
0.79
73
649
10
68
1.49
0.48
4.3
3.5
6.60
201.85
u/ml
—
5
55
24
192
1.28
0.47
2.0
1.8
—
—
—
0
0
134
1262
1.16
0.46
3.5
3.6
14.72
14.78
pmol/l
0.12
123
1145
185
1789
1.21
0.45
3.9
3.9
1.37
1.36
mmol/l
0.04
177
1661
0
15
0.00
0.41
0.0
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.9
—
13.25
—
0
15
5
34
1.48
0.40
1.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
2.2
—
16.29
—
0
18
141
1344
1.14
0.37
4.0
3.1
55.98
50.15
u/l
0.41
135
1273
11
81
1.38
0.37
1.0
1.0
—
—
—
0
0
64
701
0.88
0.35
4.0
3.8
24.23
21.50
%
0.57
29
297
6
46
1.31
0.33
1.0
1.3
—
—
—
0
0
37
327
1.16
0.30
1.7
1.7
419.66
450.79
pmol/l
0.37
29
283
7
56
1.26
0.29
5.3
2.7
83.09
157.48
mg/l
—
7
43
7
56
1.26
0.29
5.3
2.7
27.47
34.64
mg/l
—
7
43
5
75
0.66
0.26
1.6
1.8
3.98
5.42
mg/l
—
5
56
5
40
1.26
0.22
1.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
505.71
—
0
7
0
14
0.00
0.20
0.0
1.0
—
39.61
—
0
7
6
49
1.23
0.20
1.0
1.1
—
—
—
0
0
6
51
1.18
0.19
1.0
1.2
—
—
—
0
0
6
51
1.18
0.19
1.0
1.2
—
—
—
0
0
9
81
1.12
0.15
1.0
1.3
—
—
—
0
0
7
88
0.79
0.15
1.7
2.1
—
—
—
0
0
5
47
1.07
0.09
1.2
1.9
—
—
—
0
0
206
2046
1.11
0.08
30.7
19.3
138.53
139.74
g/l
0.54
206
2016
10
88
1.14
0.08
1.4
1.9
221.90
251.23
pmol/l
—
10
83
6
71
0.84
0.08
3.2
1.5
392.00
259.26
mu/l
—
6
65
6
72
0.83
0.07
1.8
2.1
—
—
—
0
0
6
73
0.82
0.07
2.7
3.9
46.00
51.81
%
—
6
73
16
149
1.08
0.05
6.3
8.4
9.38
9.34
mmol/l
0.01
16
144
53
517
1.03
0.04
2.8
2.7
0.52
0.71
ug/l
2.62
36
313
51
504
1.02
0.00
3.5
4.1
26.96
9.67
mg/mmol
0.59
41
339
20
197
1.02
0.00
1.7
1.8
—
—
—
0
0
88
877
1.01
0.00
3.7
4.2
1.63
2.17
ug/l
0.76
79
793
0
8
0.00
0.00
0.0
4.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
4.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
21.70
—
0
7
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
49.20
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
6
60
1.00
-0.00
1.5
2.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
90.83
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
81.30
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
23.81
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint REITER and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| REITER | 1.516 [1.12, 2.06] | 0.008 |
| Birth year | 0.999 [0.99, 1.01] | 0.892 |
During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 387 females with REITER died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| REITER | 1.526 [1.28, 1.82] | < 0.001 |
| Birth year | 0.983 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 189 out of 1071 males with REITER died.
Mortality risk
Mortality risk for people of age
years, who have REITER.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.168% | 0.209% |
| 5 | 1.11% | 1.463% |
| 10 | 2.728% | 3.843% |
| 15 | 5.054% | 7.025% |
| 20 | 9.186% | 12.038% |
Relationships between endpoints
↥Index endpoint: REITER – Reiter disease
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data